Ingemarsson I
Am J Obstet Gynecol. 1976 Jun 15;125(4):520-4. doi: 10.1016/0002-9378(76)90369-0.
The effect of terbutaline, a "selective" beta2-receptor stimulator, was compared with that of placebo in 30 patients in premature labor. Treatment consisted of an intravenous infusion for at least 8 hours, and then of subcutaneous injections four times daily for 3 days together with peroral treatment, which was continued until the end of week 36 of pregnancy. In 12 of 15 terbutaline-treated patients (80 per cent) premature labor was arrested beyond the treatment period, compared with three of 15 in the placebo group (20 per cent). This difference is statistically significant (p less than 0.01). No serious side effects were observed. During infusion, there was an increase in maternal heart rate. This was more pronounced in the terbutaline group (30 per cent) than in the placebo group (9 per cent). There were no adverse effects on blood pressure, but fetal tachycardia was observed more frequently in the terbutaline than in the placebo group. The results suggest that terbutaline is a safe, potent, and well-tolerated inhibitor of premature labor.
将“选择性”β₂受体激动剂特布他林的效果与安慰剂在30例早产患者中的效果进行了比较。治疗包括静脉输注至少8小时，然后每日皮下注射4次，共3天，并同时进行口服治疗，持续至妊娠36周结束。在15例接受特布他林治疗的患者中，有12例（80%）在治疗期后早产被抑制，而安慰剂组15例中有3例（20%）。这种差异具有统计学意义（p<0.01）。未观察到严重副作用。在输注期间，母体心率增加。这在特布他林组（30%）比安慰剂组（9%）更明显。对血压无不良影响，但特布他林组比安慰剂组更频繁地观察到胎儿心动过速。结果表明，特布他林是一种安全、有效且耐受性良好的早产抑制剂。
